CSF2 and COVID-19: Experts around the world have been examining COVID-19, for instance, as a possible human model of anti-MDA5 Idiopathic inflammatory myopathy (IIM), which might enhance COVID-19 treatment development: high-dose corticosteroids, human immunoglobulins, Janus kinase (JAK) inhibitors, and T cell modulators currently in trials and IL-6 inhibitors (e.g., tocilizumab), anti-GM-CSF (gimsilumab), IL-1 inhibitors (e.g., anakinra), and anti-IFNγ agents (e.g., emapalumab) could, thus, be considered as a potential treatment of COVID-19 (88).